Seeking Alpha

More on Seattle Genetics' Q4: Though results beat estimates, the company is declining to provide...

More on Seattle Genetics' Q4: Though results beat estimates, the company is declining to provide 2012 guidance for sales of its Adcetris lymphoma drug. Adcetris accounted for over 2/3 of Seattle Genetics' Q4 revenue. SGEN -7.3% AH. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector